Html code here! Replace this with any non empty raw html code and that's it.

GLP-1 therapies included in WHO’s recommendations for the first time

Date:

Share this article:

Del denne artikel:

A major shift in global obesity care is underway as the WHO formally supports modern weight-loss medications for long-term treatment.

Many people know the feeling: the cycle of diets, renewed motivation, and the frustration of slipping back into old habits.

Weight isn’t just et tal på en vægt — it follows you into everyday decisions, social situations and even your self-image. That’s why nye ændringer i global sundhedspolitik nu vækker opsigt.

A turning point in obesity treatment

For the first time, the World Health Organization (WHO) officially recommends using GLP-1–based weight-loss medication as part of long-term treatment for obesity.

The updated guidance marks a clear shift toward recognizing obesity as a chronic disease rather end a personal failure — a condition that requires ongoing medical support, much like diabetes or hypertension.

Also read: Diet shift helped one woman cut her cholesterol by 15 percent

WHO highlights that over one billion people worldwide live with obesity today, and without intervention that number may double by 2030.

Medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) can create meaningful, sustained weight reduction when combined with lifestyle support and professional oversight.

The global challenge isn’t demand — it’s access

Despite their effectiveness, very few people who could benefit from GLP-1 medications are able to get them.

High prices, insurance limitations and regional inequality make treatment inaccessible in many parts of the world.

Also read: Study identifies cellular process that could change cholesterol treatment

WHO emphasizes that global improvement requires pharmaceutical companies to reduce prices and governments to expand coverage — otherwise the tools exist, but far too few can use them.

One key recommendation for countries

Nations are encouraged to integrate GLP-1 medications into long-term obesity care, while ensuring fair pricing, equal access and proper clinical guidance.

Obesity remains one of the most widespread health challenges of our time — but for the first time, international policy is aligning with the lived reality of millions.

Artiklen er baseret på informationer fra WHO’s guidelines

Also read: New research shows how UV light triggers inflammation in skin cells

Also read: Early RSV protection may reduce childhood asthma

Other articles

Diet shift helped one woman cut her cholesterol by 15 percent

A Reddit user saw a noticeable improvement in her cholesterol after shifting most of her meals toward specific foods.

Study identifies cellular process that could change cholesterol treatment

New findings suggest that the body’s own immune cells may play a bigger role in clearing cholesterol than previously understood.

New research shows how UV light triggers inflammation in skin cells

A new study suggests that UV exposure can switch off an internal regulatory system in the skin, and allowing inflammation to escalate.

Early RSV protection may reduce childhood asthma

A growing body of evidence suggests that protecting newborns from RSV could influence children’s long-term respiratory health.

Diet shift helped one woman cut her cholesterol by 15 percent

A Reddit user saw a noticeable improvement in her cholesterol after shifting most of her meals toward specific foods.

Study identifies cellular process that could change cholesterol treatment

New findings suggest that the body’s own immune cells may play a bigger role in clearing cholesterol than previously understood.

New research shows how UV light triggers inflammation in skin cells

A new study suggests that UV exposure can switch off an internal regulatory system in the skin, and allowing inflammation to escalate.